GSK gives Wave a lift with genetic medicine deal
Bio Pharma Dive
DECEMBER 14, 2022
A four-year agreement between the companies comes with $170 million in cash and equity for Wave, which in recent years has dealt with clinical setbacks
Medicine Related Topics 
259 
CARsgen and Huadong Medicine to commercialise CT053 in mainland China
Pharmaceutical Technology
JANUARY 16, 2023
CARsgen Therapeutics has announced a col labor ation with Huadong Medicine to commercialise zevorcabtagene autoleucel (zevor-cel), CT053, in mainland China. Under the collaboration, Huadong Medicine will have the exclusive right to commercialise CARsgen’s CT053 in mainland China.
Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Lilly puts $700M into genetic medicine institute
Bio Pharma Dive
FEBRUARY 22, 2022
Building on Lilly's acquisition of Prevail Therapeutics, the Boston-based facility will use RNA- and DNA-based technologies to develop new drugs, while also supporting biotech startups in the area
Lilly and ProQR to expand genetic medicine development agreement
Pharmaceutical Technology
DECEMBER 23, 2022
Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The post Lilly and ProQR to expand genetic medicine development agreement appeared first on Pharmaceutical Technology.
Pfizer expands not-for-profit pledge to include more medicines
Bio Pharma Dive
JANUARY 17, 2023
The pharma is now committing to providing all of the roughly 500 products in its portfolio, including antibiotics and cancer drugs, to 45 lower-income countries
Building a bridge between science and medicine at Regeneron
Bio Pharma Dive
OCTOBER 3, 2022
Michael Klingler shares how the Biostatistics & Data Management team solve unsolvable problems together
Blacksmith Medicines to merge with Forge Therapeutics
Pharmaceutical Technology
JANUARY 3, 2023
Blacksmith Medicines has signed a definitive merger agreement with Forge Therapeutics to create a combined entity that will discover and develop medicines targeting a large class of proteins called metalloenzymes.
Testing Facility Called “Game Changer” in Regenerative Medicine
Pharma Mirror
AUGUST 30, 2022
The post Testing Facility Called “Game Changer” in Regenerative Medicine appeared first on Pharma Mirror Magazine. Pharmaceutical Articles Industry article Pharmaceutical articles pharmaceutical testing Regenerative MedicineThe RegeneratOR Test Bed is an exciting game changer.
Building a bridge between science and medicine at Regeneron
Bio Pharma Dive
AUGUST 29, 2022
Wilson Caldwell talks about how he and the clinical operations team turn promise into reality for patients every day
Modernizing cell culture processes for the next wave of genomic medicine
Pharmaceutical Technology
FEBRUARY 3, 2023
The field of genomic medicine has reached a true turning point. In June 2022, the European Medicines Agency approved an adeno-associated viral (AAV) vector-based therapy for adults with Hemophilia A, making the treatment available to an estimated 3,200 eligible patients. [1]
Prime Medicine raises $175M in one of the year’s largest biotech IPOs
Bio Pharma Dive
OCTOBER 20, 2022
The gene editing startup is one of less than two dozen biotech companies to debut on Wall Street this year, as the pace of IPOs remains far off last year’s trajectory
Bayer, Amgen back ReCode's plan to broaden genetic medicine's reach
Bio Pharma Dive
JUNE 29, 2022
The two drugmakers joined a long list of investors, including Pfizer and Sanofi, that have been funding the startup’s plan to develop a new type of lipid nanoparticle technology
Editas to seek partner for CRISPR medicine after lackluster study results
Bio Pharma Dive
NOVEMBER 17, 2022
While the biotech will not develop the gene editing therapy further on its own, CEO Gilmore O’Neill claimed the data are still a meaningful demonstration of what CRISPR can accomplish
Managing drug shortages: Getting medicines to patients in need
Pharmaceutical Technology
DECEMBER 6, 2022
Ongoing drug shortages are not a new occurrence, but a rise in shortages following the pandemic and other global events is leaving many patients unable to access the medicines they need. Enabling Access to Medicines: What Manufacturers and Patients Need to Know. <p>Early
Intrinsic Medicine enters merger with Phoenix Biotech
Pharmaceutical Technology
NOVEMBER 1, 2022
Intrinsic Medicine has signed a definitive business combination agreement with special purpose acquisition (SPAC) firm Phoenix Biotech Acquisition to create a public company. The post Intrinsic Medicine enters merger with Phoenix Biotech appeared first on Pharmaceutical Technology.
Third Rock-backed Faze Medicines shutters two years after launch
Bio Pharma Dive
NOVEMBER 10, 2022
The startup, which focused on biomolecular condensates, is calling it quits after “the science did not progress sufficiently to meet our bar for further investment,” a spokesperson said
Is digital the future of medicine?
World of DTC Marketing
DECEMBER 4, 2020
Digital medicine has been thrust into the spotlight because of the pandemic and the media hype is in overdrive. A study of some 16m American ones just reported in jama Internal Medicine , a journal, found that their use of telemedicine surged 30-fold between January and June.
For ALS patients, doctors, a new medicine reignites concerns about healthcare access
Bio Pharma Dive
DECEMBER 15, 2022
Relyvrio, a drug developed by Amylyx Pharmaceuticals, is in high demand in ALS clinics across the U.S. Though some patients are already getting it, insurance coverage and out-of-pocket costs remain a source of anxiety
Scottish Medicines Consortium recommends Merck’s Tepmetko
Pharma Times
JANUARY 18, 2023
Therapy is the first oral MET inhibitor treatment option for certain advanced NSCLC adult patients
Magazine: Medicine in outer space
Pharmaceutical Technology
OCTOBER 24, 2022
In this issue, we take a look at tools and guidelines being developed to not just study but also manufacture medicines away from the planet. The post Magazine: Medicine in outer space appeared first on Pharmaceutical Technology. Space agencies and private companies the world over are inching closer to their plans of taking humans to the moon and eventually to Mars.
Worms as a model for personalized medicine
Scienmag
JULY 19, 2022
Tailoring a person’s diet or medicine based on their genomes has been a goal of the medical community for decades, but the strategy has not been widely successful because people metabolize chemicals differently. Medicine & Health Medicine model personalized worms
Pfizer buys into Biohaven's fast-selling migraine medicine
Bio Pharma Dive
NOVEMBER 9, 2021
The pharmaceutical giant will pay Biohaven $500 million for ex-U.S. rights to rimegepant — a sizable licensing deal, though not the buyout that some of the biotech's investors appeared to be hoping for
Pfizer pledges not-for-profit sale of medicines in low-income countries
Bio Pharma Dive
MAY 25, 2022
The new initiative commits Pfizer to supplying current and future branded medicines at lower cost to 45 countries The pharma has been criticized for not doing enough to make its COVID-19 vaccine and pill available globally.
Prime Medicine becomes the next high-profile biotech to test the IPO waters
Bio Pharma Dive
SEPTEMBER 26, 2022
The startup, which launched last year with $315 million in funding and plans to advance a new form of gene editing, is one of the first big venture-backed biotechs in several months to seek an IPO
Crossed wires? Mixed messages on medicines
Pharma Phorum
JANUARY 20, 2023
Leela Barham argues that the latest operational guidance for the NHS in England continues to illustrate a disconnect between the messages in big-ticket policy documents from the central government and the messages from the NHS in England on medicines.
Belharra and Genentech partner for small molecule medicines development
Pharmaceutical Technology
JANUARY 4, 2023
Belharra Therapeutics and Roche Group member Genentech have announced a partnership for the discovery and development of new small molecule medicines across several therapeutic areas.
Blueprint Medicines announces financing partnerships for $1.25bn
Pharmaceutical Technology
JULY 1, 2022
Blueprint Medicines has entered strategic financing partnerships for up to $1.25bn with life sciences-focused investors Sixth Street and Royalty Pharma. The post Blueprint Medicines announces financing partnerships for $1.25bn appeared first on Pharmaceutical Technology.
Microbiota medicine: towards clinical revolution
Scienmag
MARCH 31, 2022
Biology clinical Medicine microbiota revolutionAfter the last meeting of the International Society of Microbiota (ISM), a well-documented report and statement were published.
A new startup gets Takeda's backing to take complex genetic medicines 'off the shelf'
Bio Pharma Dive
FEBRUARY 11, 2021
Ensoma Therapeutics debuts with a lucrative alliance with the Japanese pharma and an unusual way to deliver genetic medicines into the body
Digital medicine company Akili gets cold market reception after blank-check merger
Bio Pharma Dive
AUGUST 22, 2022
After spiking on news of the merger’s close, shares in the ADHD treatment developer fell sharply in trading Monday and again on Tuesday
Lilly pays $880M for Prevail, pushing further into genetic medicine
Bio Pharma Dive
DECEMBER 15, 2020
The acquisition marks a significant bet by Lilly on gene therapy's potential to address tough-to-treat neurological disorders like Parkinson's disease
Toppan Subsidiary Okapi Pharmacy Launches Medicine Delivery Service
Pharma Mirror
AUGUST 8, 2020
The post Toppan Subsidiary Okapi Pharmacy Launches Medicine Delivery Service appeared first on Pharma Mirror Magazine. Pharmaceutical News Medicine Delivery Service Okapi Toppan
Nanochannels light the way towards new medicine
Scienmag
JUNE 16, 2022
Social & Behavioral Science light Medicine nanochannelsTo develop new drugs and vaccines, detailed knowledge about nature’s smallest biological building blocks – the biomolecules – is required.
Driving clinical trial innovation forward with precision medicine
Pharma Phorum
JANUARY 17, 2023
Late last year, pharmaphorum spoke with AstraZeneca’s Ben Challis, VP and head of translational science and experimental medicine, cardiovascular, renal, and metabolism (CVRM), together with Magnus Jörnten-Karlsson, executive director of Unify.
Lack of medicines in Greece and the solution of Generics
Pharma Tutor
JANUARY 10, 2023
Lack of medicines in Greece and the solution of Generics. admin. Tue, 01/10/2023 - 15:46. Georgios-Marios Bolmpasis. MPharm Student University of Athens. Vice President of Pharmacy Students Association(Athens
Diving arising antimalarial medicine resistance in Africa
The Pharma Data
NOVEMBER 19, 2022
Diving arising antimalarial medicine resistance in Africa. Although antimalarial medicine resistance is a serious cause for concern, artemisinin- grounded combination curatives( ACTs) remain the stylish available treatment for uncomplicatedP. WHO is launching moment a new strategy to respond to the critical problem of antimalarial medicine resistance in Africa. ACTs combine an artemisinin outgrowth( artesunate, artemether or dihydroartemisinin) with a mate medicine.
RVAC Medicines, A*STAR partner for mRNA manufacturing expertise
Pharmaceutical Technology
NOVEMBER 21, 2022
RVAC Medicines has signed a master research partnership agreement with the Agency for Science, Technology and Research (A*STAR) for analysing and developing solutions to build messenger ribonucleic acid (mRNA) manufacturing and analytics expertise in Singapore.
Multi-drug precision medicine cancer trial begins
Pharma Times
NOVEMBER 24, 2022
Patients on the trial will have one of the particular genetic mutations among rare cancers
LifeArc and MRC launch toolkit to navigate medicines repurposing
Pharma Times
OCTOBER 10, 2022
Medicines repurposing offers new avenues for treating a range of common and rare diseases
Self-reported Sexual Harassment and Subsequent Reporting Among Internal Medicine Residents in the US
JAMA Internal Medicine
JANUARY 16, 2023
This study uses survey data to describe the types of sexual harassment experienced by internal medicine residents, their knowledge of reporting mechanisms, their reporting intentions and actions, and satisfaction with reporting outcomes
Call to arms as UK falls back in medicines manufacturing
Pharma Phorum
JANUARY 24, 2023
Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition. The post Call to arms as UK falls back in medicines manufacturing appeared first on.
Gemini enters business combination deal with Disc Medicine
Pharmaceutical Technology
AUGUST 11, 2022
Gemini Therapeutics has signed a definitive agreement to merge with Disc Medicine in an all-stock deal to create a clinical-stage biopharmaceutical company. The merged company is expected to be named Disc Medicine, which will have corporate headquarters in Watertown, Massachusetts, US.
German Merck buys manufacturer of key component in mRNA medicines
Bio Pharma Dive
JANUARY 6, 2022
Merck KGaA is buying Indianapolis-based Exelead, a specialist in the lipid nanoparticles used to ferry mRNA into the body, for $780 million in cash
Let's personalize your content